Related references
Note: Only part of the references are listed.Management of NFAs: medical treatment
Naomi Even-Zohar et al.
PITUITARY (2018)
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas
Helene Lasolle et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Aggressive Pituitary Adenomas: The Dark Side of the Moon
Stefano M. Priola et al.
WORLD NEUROSURGERY (2017)
The 2017 World Health Organization classification of tumors of the pituitary gland: a summary
M. Beatriz S. Lopes
ACTA NEUROPATHOLOGICA (2017)
Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas
Marco Losa et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Maria Fleseriu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90Y-DOTATATE: case report
Joanna Waligorska-Stachura et al.
JOURNAL OF NEUROSURGERY (2016)
Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
Daniel Bengtsson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Aggressive Pituitary Tumors
Eleftherios Chatzellis et al.
NEUROENDOCRINOLOGY (2015)
Somatostatin receptor ligands and resistance to treatment in pituitary adenomas
Daniel Cuevas-Ramos et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
Jan Komor et al.
PITUITARY (2014)
Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation
Jillian Maclean et al.
PITUITARY (2014)
ACTH-secreting Crooke cell carcinoma of the pituitary
Gabor L. Kovacs et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment
S. Baldari et al.
Pituitary (2012)
Resistance to Somatostatin Analogs in Acromegaly
Annamaria Colao et al.
ENDOCRINE REVIEWS (2011)
Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease - Report of a Case and Literature Review
Lorenzo Curto et al.
THESCIENTIFICWORLDJOURNAL (2010)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review
Umberto Goglia et al.
PITUITARY (2008)
Surgical treatment of giant pituitary adenomas: Strategies and results in a series of 95 consecutive patients
Pietro Mortini et al.
NEUROSURGERY (2007)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
DJ Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
